New Breakthrough T1D publications highlight unmet needs and demographics of the T1D population
Breakthrough T1D recently published two peer-reviewed journal articles. One detailed burdensome unmet needs in the T1D community and identified key steps we can take to meet these needs. The other used real-world data to better understand American T1D demographics and predict changes in the next decade.
Challenges and solutions: The present and future of cell therapies for T1D
Breakthrough T1D is funding research that supports manufactured islet cell source, survival, and protection and is also driving initiatives to unlock access to manufactured islet therapies for people with T1D.
Breakthrough T1D 2025 Government Day: 4 amazing days, 485 Congressional meetings, 370 sore feet
Breakthrough T1D headed to Washington D.C. where advocates held nearly 500 meetings with Members of Congress on behalf of the T1D community.
2024 greatest T1D hits: A glance at this year’s achievements
While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures and improving everyday life with T1D. This wouldn’t have been possible without each and every one of you and your continued support of our mission as we drive toward cures for T1D. Here are the […]
New ICD-10 Codes Will Help the T1D Community
On October 1st, the T1D community got a big win: the Centers for Medicare and Medicaid Servies (CMS) introduced a unique ICD-10 code for stage 2 type 1 diabetes (T1D). This addresses a significant gap in clinical care. Prior to this change, clinicians had limited options for coding stage 2 T1D, which resulted in inaccurate […]
Advocating for progress and access
With the support of our grassroots advocates, our work helps advance treatments, influence policy, and improve access to care for those worldwide who need it.
Breaking through to Congress at 2024 Government Day
Our Advocates traveled to D.C. to reintroduce our organization and champion legislation and policy for the T1D community.
Beating the Odds: The Improbable Story of How Perseverance, Belief, and Luck Led to the Approval of the First Life-Changing Immune Therapy for Type 1 Diabetes
The true story of how Tzield (teplizumab), the first disease-modifying therapy approved for use in delaying type 1 diabetes (T1D) onset, made it to market.
What Drug Will Be the Next Tzield?
In 2023 alone, there have been several important papers published on disease-modifying therapies (DMT) for type 1 diabetes. This blog explains everything you need to know about several DMTs.
The Smallest Artificial Pancreas System Receives FDA Clearance
Tandem Mobi—a miniature-sized insulin pump, for use with Tandem’s Control-IQ™ technology and a compatible CGM—received FDA clearance.
